Nexvet to Host Symposium at American College of Veterinary Internal Medicine (ACVIM) Forum to Present Additional NV-01 Pivota...
May 11 2016 - 5:30AM
Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer,
today announced it will host a symposium to present expanded
pivotal safety and efficacy data for NV-01 (ranevetmab), a novel
caninized anti-nerve growth factor (NGF) monoclonal antibody (mAb)
under clinical investigation for the control of pain associated
with osteoarthritis in dogs, and the latest clinical data for
NV-02, the analogous felinized mAb for cats, at the ACVIM Forum in
Denver, Colorado, on June 9th, 2016. In addition, Nexvet
clinical collaborator Dr. Margaret Gruen of North Carolina State
University’s Comparative Pain Research Program will present an
extended clinical research abstract at ACVIM relating to Nexvet’s
proof-of-concept efficacy study of NV-02 entitled “Feline
Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with
Degenerative Joint Disease-Associated Pain” at 9AM UTC on June
11th.
The Company’s seminar on June 9th at 6:30AM - 8:30AM UTC will
showcase the underlying biology of NGF, clinical study design of
its chronic pain programs, as well as provide an update on
ranevetmab’s pivotal safety and efficacy data in dogs with
osteoarthritis. This study was announced to have met its primary
efficacy endpoint (p ≤0.038) in November 2015. Professor Duncan
Lascelles of North Carolina State University’s Comparative Pain
Research Program, a leader in veterinary and comparative pain
management, will be the featured speaker, providing the context for
chronic pain in dogs and cats, including its measurement and unmet
needs. Nexvet speakers will include: Dr Juergen Horn, Chief Product
Development Officer, Dr. Colin Giles, Vice President, Clinical and
Regulatory, and Dr. Jane Eagleson, Director of Clinical and
Regulatory Affairs.
“As a company with programs in late-stage clinical development,
we will increasingly utilize premier veterinary specialist
conferences to engage with key opinion leaders and practicing
veterinarians about biologics and Nexvet’s product candidates. Our
market surveys have unequivocally demonstrated that a monthly
subcutaneous injection for chronic pain indications in both dogs
and cats is a very attractive concept and would be welcomed by
veterinarians. mAbs targeting NGF are an entirely novel modality
for veterinary pain management and are based on substantial
validation from human clinical trials, validation we are the first
to demonstrate from pivotal companion animal studies,” commented
Dr. Mark Heffernan, Chief Executive Officer of Nexvet.
About Nexvet
(www.nexvet.com)
Nexvet is a veterinary biologics developer focused on
transforming the therapeutic market for companion animals, such as
dogs and cats, by developing and commercializing novel,
species-specific biologics. Nexvet’s proprietary PETization™
platform is designed to rapidly design monoclonal antibodies (mAbs)
that are recognized as “self” or “native” by an animal’s immune
system, a property Nexvet refers to as “100% species-specificity.”
Nexvet’s product candidates also build upon the safety and efficacy
data from clinically tested human therapies, thereby reducing
clinical risk and development cost.
Nexvet is leveraging diverse global expertise and incentives to
build a vertically integrated biopharmaceutical company, which
conducts drug discovery in Australia, conducts clinical
development in the United States and Europe and is
growing its biomanufacturing capabilities in Ireland.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements consist of all statements other
than statements of historical fact, including statements regarding
our future results of operations and financial position, results of
any current or future pivotal safety and efficacy study, future
expenditures relating to our lead product candidates, time for
completion of any of our studies or facilities updates, ability to
develop our pipeline of product candidates, business strategy,
prospective products, ability to successfully manufacture our own
product candidates, ability to meet conditions for the receipt of
government grants, ability to qualify for conditional licensure or
obtain product approvals, research and development costs, timing
and likelihood of success, plans and objectives of management for
future operations, and future results of current and anticipated
products. These statements relate to future events or to our future
financial performance and involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. The words “anticipate,”
“assume,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “might,” “objective,” “plan,” “potential,”
“predict,” “project,” “position,” “seek,” “should,” “target,”
“will,” “would,” or the negative of these terms or other similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are based
on current expectations, estimates, forecasts and projections about
our business and the industry in which we operate, and management’s
beliefs and assumptions are not guarantees of future performance or
development and involve known and unknown risks, uncertainties and
other factors.
Factors that could cause actual results to differ materially
from our expectations expressed in this report include those
summarized under Risk Factors in our reports on Forms 10-Q and 10-K
and the other documents we file from time to time with the
Securities and Exchange Commission. Given these risks and
uncertainties, you should not place undue reliance on these
forward-looking statements. Also, forward-looking statements
represent management’s beliefs and assumptions only as of the date
of this press release. Except as required by law, we do not intend,
and undertake no obligation, to revise or update these
forward-looking statements, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future.
Further information:
Investors
Candice Knoll
Blueprint Life Science Group
+1 415-375-3340 Ext. 4
cknoll@bplifescience.com
Media
Jessica Burns
Berry & Company Public Relations
+1 212-253-8881
jburns@berrypr.com
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From May 2024 to Jun 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Jun 2023 to Jun 2024